Neutrophils-related host factors associated with severe disease and fatality in patients with influenza infection.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
31 07 2019
Historique:
received: 22 10 2018
accepted: 28 06 2019
entrez: 2 8 2019
pubmed: 2 8 2019
medline: 18 12 2019
Statut: epublish

Résumé

Severe influenza infection has no effective treatment available. One of the key barriers to developing host-directed therapy is a lack of reliable prognostic factors needed to guide such therapy. Here, we use a network analysis approach to identify host factors associated with severe influenza and fatal outcome. In influenza patients with moderate-to-severe diseases, we uncover a complex landscape of immunological pathways, with the main changes occurring in pathways related to circulating neutrophils. Patients with severe disease display excessive neutrophil extracellular traps formation, neutrophil-inflammation and delayed apoptosis, all of which have been associated with fatal outcome in animal models. Excessive neutrophil activation correlates with worsening oxygenation impairment and predicted fatal outcome (AUROC 0.817-0.898). These findings provide new evidence that neutrophil-dominated host response is associated with poor outcomes. Measuring neutrophil-related changes may improve risk stratification and patient selection, a critical first step in developing host-directed immune therapy.

Identifiants

pubmed: 31366921
doi: 10.1038/s41467-019-11249-y
pii: 10.1038/s41467-019-11249-y
pmc: PMC6668409
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3422

Références

Curr Top Microbiol Immunol. 2015;386:3-22
pubmed: 25267464
Am J Pathol. 2011 Jul;179(1):199-210
pubmed: 21703402
Brief Bioinform. 2014 Mar;15(2):195-211
pubmed: 23698722
Cell. 2013 Jul 3;154(1):197-212
pubmed: 23827683
Nat Med. 2006 Oct;12(10):1203-7
pubmed: 16964257
JAMA. 2016 Apr 12;315(14):1469-79
pubmed: 26975785
Crit Care. 2012 Aug 16;16(4):R157
pubmed: 22898401
Cell Mol Immunol. 2016 Jan;13(1):3-10
pubmed: 26189369
J Virol. 2010 Dec;84(24):12832-40
pubmed: 20861262
PLoS One. 2012;7(10):e46581
pubmed: 23056353
Nat Med. 2012 Jan 29;18(2):274-80
pubmed: 22286307
Am J Respir Crit Care Med. 2016 Oct 15;194(8):961-973
pubmed: 27064380
PLoS One. 2016 Jun 17;11(6):e0157903
pubmed: 27315117
Am J Physiol Lung Cell Mol Physiol. 2015 Nov 15;309(10):L1041-6
pubmed: 26408556
Semin Nucl Med. 1978 Oct;8(4):283-98
pubmed: 112681
PLoS Pathog. 2015 Jun 12;11(6):e1004869
pubmed: 26070066
Immunol Cell Biol. 2007 Feb-Mar;85(2):85-92
pubmed: 17213831
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Nat Med. 2009 Mar;15(3):277-84
pubmed: 19234462
Lancet Infect Dis. 2014 Jan;14(1):57-69
pubmed: 24239327
J Infect Pulm Dis. 2016;2(2):
pubmed: 27868106
Med Mal Infect. 2014 Oct;44(10):455-63
pubmed: 25169939
OMICS. 2014 Mar;18(3):167-83
pubmed: 24512282
Antimicrob Agents Chemother. 2011 May;55(5):1831-42
pubmed: 21343462
PLoS One. 2011 Mar 08;6(3):e17186
pubmed: 21408152
Immunol Cell Biol. 2009 Nov-Dec;87(8):579-89
pubmed: 19721456
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
Crit Care. 2013 Feb 13;17(1):R30
pubmed: 23406535
Nat Commun. 2015 May 13;6:6833
pubmed: 25967273
Influenza Other Respir Viruses. 2009 Jul;3(4):129-42
pubmed: 19627370
PLoS One. 2013;8(1):e52198
pubmed: 23326326
Lancet. 2015 May 2;385(9979):1729-1737
pubmed: 25640810
Curr Opin Hematol. 2007 Nov;14(6):688-93
pubmed: 17898576
Chest. 2017 Dec;152(6):1151-1158
pubmed: 28823812
Nature. 2007 Jan 18;445(7125):319-23
pubmed: 17230189
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Biochemistry (Mosc). 2014 Dec;79(12):1286-96
pubmed: 25716722
J Biopharm Stat. 2010 Mar;20(2):281-300
pubmed: 20309759
Eur Respir J. 2015 May;45(5):1463-78
pubmed: 25792631
J Biol Chem. 2017 Mar 24;292(12):5070-5088
pubmed: 28130444
PLoS Med. 2011 Jul;8(7):e1001053
pubmed: 21750667
Cell Host Microbe. 2009 Sep 17;6(3):207-17
pubmed: 19664979
Crit Care. 2011;15(5):231
pubmed: 22017882
Lancet Respir Med. 2014 Jun;2(6):445-54
pubmed: 24717637
J Virol. 2013 Mar;87(6):3039-52
pubmed: 23283961

Auteurs

Benjamin M Tang (BM)

Department of Intensive Care Medicine, Nepean Hospital, Sydney, Australia. benjamin.tang@sydney.edu.au.
Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Sydney, Australia. benjamin.tang@sydney.edu.au.
Respiratory Tract Infection Research Node, Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney, Australia. benjamin.tang@sydney.edu.au.

Maryam Shojaei (M)

Department of Intensive Care Medicine, Nepean Hospital, Sydney, Australia.
Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Sydney, Australia.

Sally Teoh (S)

Department of Intensive Care Medicine, Nepean Hospital, Sydney, Australia.

Adrienne Meyers (A)

National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Department of Medical Microbiology and Infectious Disease, University of Manitoba, Winnipeg, Canada.

John Ho (J)

National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Department of Medical Microbiology and Infectious Disease, University of Manitoba, Winnipeg, Canada.

T Blake Ball (TB)

National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Department of Medical Microbiology and Infectious Disease, University of Manitoba, Winnipeg, Canada.

Yoav Keynan (Y)

Department of Internal Medicine, Medical Microbiology and Community Health Sciences, University of Manitoba, Winnipeg, Canada.

Amarnath Pisipati (A)

Department of Chemistry and Biological Chemistry, Harvard University, Cambridge, MA, USA.

Aseem Kumar (A)

Department of Chemistry and Biochemistry, Laurentian University, Laurentian, Canada.

Damon P Eisen (DP)

Townsville Hospital, Townsville, Queensland, Australia.

Kevin Lai (K)

Department of Emergency Medicine, Westmead Hospital, Sydney, Australia.

Mark Gillett (M)

Department of Emergency Medicine, Royal North Shore Hospital, Sydney, Australia.

Rahul Santram (R)

Department of Emergency Medicine, St. Vincent Hospital, Sydney, Australia.

Robert Geffers (R)

Genome Analytics, Helmholtz Centre for Infection Research, Braunschweig, Germany.

Jens Schreiber (J)

Otto-von-Guerike University of Magdeburg, Clinic of Pneumology, Magdeburg, Germany.

Khyobeni Mozhui (K)

Department of Preventive Medicine, University of Tennessee Health Science Centre, Memphis, TN, USA.

Stephen Huang (S)

Department of Intensive Care Medicine, Nepean Hospital, Sydney, Australia.

Grant P Parnell (GP)

Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Sydney, Australia.

Marek Nalos (M)

Department of Intensive Care Medicine, Nepean Hospital, Sydney, Australia.
Department of Internal Medicine, Medical Faculty Plzen, Charles University Prague, Staré Město, Czech Republic.

Monika Holubova (M)

Biomedical Centre, Medical Faculty Plzen, Charles University Prague, Staré Město, Czech Republic.

Tracy Chew (T)

Sydney Informatic Hub, The University of Sydney, Sydney, Australia.

David Booth (D)

Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Sydney, Australia.

Anand Kumar (A)

Section of Critical Care Medicine and Section of Infectious Diseases, Departments of Medicine, Medical Microbiology and Pharmacology, University of Manitoba, Winnipeg, Canada.

Anthony McLean (A)

Department of Intensive Care Medicine, Nepean Hospital, Sydney, Australia.

Klaus Schughart (K)

Department of Infection Genetics, Helmholtz Centre for Infection Research, Braunschweig, Germany.
University of Veterinary Medicine, Hannover, Germany.
Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Centre, Memphis, TN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH